Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 1366 to 1380 of 1516 results for patients and public

  1. Masitinib for treating relapsed or refractory peripheral T-cell non-Hodgkin lymphoma [ID1125]

    Discontinued Reference number: GID-TA11173

    Technology appraisal guidance
    Discontinued

  2. Lymphoma (diffuse large B-cell, untreated) – liposomal vincristine [ID1123]

    Discontinued Reference number: GID-TA11208

    Technology appraisal guidance
    Discontinued

  3. Pazopanib for adjuvant treatment of locally advanced renal cell carcinoma [ID1091]

    Discontinued Reference number: GID-TA11240

    Technology appraisal guidance
    Discontinued

  4. Canakinumab and tocilizumab for treating systemic juvenile idiopathic arthritis [ID983]

    Discontinued Reference number: GID-TA11241

    Technology appraisal guidance
    Discontinued

  5. Triptorelin for the adjuvant treatment of early breast cancer in premenopausal women [ID976]

    Discontinued Reference number: GID-TA11261

    Technology appraisal guidance
    Discontinued

  6. Ataluren for treating cystic fibrosis in people with a CFTR gene nonsense mutation [ID955]

    Discontinued Reference number: GID-TA11262

    Technology appraisal guidance
    Discontinued

  7. Dostarlimab with docetaxel for treating advanced non-small-cell lung cancer after anti-PD-L1 treatment and chemotherapy [ID6530]

    Discontinued Reference number: GID-TA11655

    Technology appraisal guidance
    Discontinued

  8. Cendakimab for treating eosinophilic oesophagitis in people 12 years TS ID 12088

    Discontinued Reference number: GID-TA11702

    Technology appraisal guidance
    Discontinued

  9. Iclepertin for treating cognitive impairment associated with schizophrenia [ID6483]

    In development Reference number: GID-TA11647 Expected publication date: TBC

    Technology appraisal guidance
    In development

  10. ALXN1840 for treating Wilson disease [ID6422]

    In development Reference number: GID-TA11449 Expected publication date: TBC

    Technology appraisal guidance
    In development

  11. Leukocyte interleukin in combination for neoadjuvant treatment of resectable locally advanced squamous cell head and neck cancer [ID6390]

    In development Reference number: GID-TA11475 Expected publication date: TBC

    Technology appraisal guidance
    In development

  12. Dostarlimab with chemotherapy for untreated and with niraparib for maintenance treatment of advanced non-mucinous epithelial ovarian, fallopian tube or primary peritoneal cancer [ID6311]

    In development Reference number: GID-TA11367 Expected publication date: TBC

    Technology appraisal guidance
    In development

  13. Nitazoxanide for treating the common cold in people 12 years and over [ID4049]

    In development Reference number: GID-TA11128 Expected publication date: TBC

    Technology appraisal guidance
    In development

  14. Selpercatinib for treating RET fusion-positive advanced solid tumours in people aged 12 and over with no other treatment options [ID6273]

    In development Reference number: GID-TA11301 Expected publication date: TBC

    Technology appraisal guidance
    In development

  15. BI 907828 for untreated dedifferentiated advanced liposarcoma [ID6296]

    In development Reference number: GID-TA11344 Expected publication date: TBC

    Technology appraisal guidance
    In development